Lokelma Powder, For Suspension
Product Images NDC 0310-1105
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lokelma (NDC 0310-1105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Figure 2)
This is a list of medication doses, including Amlodipine, Atorvastatin, Clopidogrel, Dabigatran, Furosemide, Glipizide, Levothyroxine, Thyroxine, Triiodothyronine, Losartan, and Warfarin. There are also measurements for AUC and Cmax for each medication. The text ends with a ratio for LOKELMA plus co-administered drug versus co-administered drug alone.*
Figure 3 (Figure 3)
This appears to be a table of measurements for serum potassium levels in a study involving different doses of medication and a placebo. The table shows the mean serum potassium levels with a 95% confidence interval, as well as the number of participants in each group at different timepoints of the study. There is also a mention of a primary endpoint assessment. However, without further context or information, it is unclear what type of study this is and what the medication being tested is.*
Figure 4 (Figure 4)
Image 01
Lokelma 10 mg Ndc 0310-1110-30 Carton (Lokelma 10mg Ndc0310 1110 30 Carton Pdp)
Lokelma 5 G Ndc 0310-1105-30 Carton (Lokelma 5g Ndc0310 1105 30 Carton Pdp)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.